<?xml version='1.0' encoding='utf-8'?>
<document id="29498038"><sentence text="Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab." /><sentence text="This open-label drug-drug interaction study assessed whether blockade by dupilumab of interleukin (IL)-4 and IL-13 signaling affects the pharmacokinetics of drugs metabolized by cytochrome P450 (CYP450) enzymes" /><sentence text=" The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2, and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300â€‰mg weekly) in 14 patients with moderate-to-severe atopic dermatitis"><entity charOffset="62-71" id="DDI-PubMed.29498038.s3.e0" text="midazolam" /><entity charOffset="73-83" id="DDI-PubMed.29498038.s3.e1" text="omeprazole" /><entity charOffset="85-95" id="DDI-PubMed.29498038.s3.e2" text="S-warfarin" /><entity charOffset="97-105" id="DDI-PubMed.29498038.s3.e3" text="caffeine" /><entity charOffset="111-121" id="DDI-PubMed.29498038.s3.e4" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e0" e2="DDI-PubMed.29498038.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e0" e2="DDI-PubMed.29498038.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e0" e2="DDI-PubMed.29498038.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e0" e2="DDI-PubMed.29498038.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e0" e2="DDI-PubMed.29498038.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e1" e2="DDI-PubMed.29498038.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e1" e2="DDI-PubMed.29498038.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e1" e2="DDI-PubMed.29498038.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e1" e2="DDI-PubMed.29498038.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e2" e2="DDI-PubMed.29498038.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e2" e2="DDI-PubMed.29498038.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e2" e2="DDI-PubMed.29498038.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e3" e2="DDI-PubMed.29498038.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29498038.s3.e3" e2="DDI-PubMed.29498038.s3.e4" /></sentence><sentence text=" Dupilumab had no clinically relevant effects on the pharmacokinetics of CYP450 substrates, provided substantial clinical benefit, and was generally well tolerated" /><sentence text=" Only one serious adverse event was reported, an episode of systemic inflammatory response syndrome that resolved after treatment was discontinued" /><sentence text=" In summary, blockade of IL-4/IL-13 signaling in patients with type 2 inflammation does not appear to significantly affect CYP450 enzyme activities; the use of dupilumab in atopic dermatitis patients is unlikely to influence the pharmacokinetics of CYP450 substrates" /><sentence text="" /></document>